최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Journal of Korean biological nursing science, v.19 no.2, 2017년, pp.107 - 112
김상희 (계명대학교 간호대학.계명대학교 간호과학연구소)
Purpose: The purpose of this study was to identify the lipid profile ratios as factors affecting disease progress in patients with high-grade primary brain cancers undergoing concurrent chemoradiotherapy (CCRT) and adjuvant chemotherapy. Methods: The levels of lipid profile ratios were evaluated by ...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
악성 뇌종양의 치료법이 목적으로 하는 것은 무엇인가? | 악성 뇌종양의 치료법은 진단 후 종양제거술로 최대한 종양을 제거하고 temozolomide의 경구용 항암화학요법과 방사선 치료를 시행하여 환자의 기대여명을 연장하거나 증상 또는 국소적 기능장애의 완화를 목적으로 한다[3]. 동시 항암화학방사선요법(concurrent chemoradiotherapy, CCRT)은 경구용 항암제와 방사선 요법을 동시에 시행하는것으로 다른 치료법에 비해 기대여명을 높이는 것으로 알려져 있다. | |
동시 항암화학방사선요법이란 무엇인가? | 악성 뇌종양의 치료법은 진단 후 종양제거술로 최대한 종양을 제거하고 temozolomide의 경구용 항암화학요법과 방사선 치료를 시행하여 환자의 기대여명을 연장하거나 증상 또는 국소적 기능장애의 완화를 목적으로 한다[3]. 동시 항암화학방사선요법(concurrent chemoradiotherapy, CCRT)은 경구용 항암제와 방사선 요법을 동시에 시행하는것으로 다른 치료법에 비해 기대여명을 높이는 것으로 알려져 있다. 악성 뇌종양 환자는 6주동안 방사선치료를 시행하면서(5일/주) 경구용 항암제 temozolomide 75 mg/m2를 매일 42-49일동안 복용하고 이후 항암제를 증량하여 6 cycle의 보조항암화학요법을 받게 된다[4]. | |
동시 항암화학방사선요법의 예후에 영향을 미치는 요인들은 무엇인가? | 5-2년 미만으로 알려져 있으며 환자의 예후와 관련된 요인으로 수술 전 종양의 크기와 위치, 악성도, 종양적출정도, 다발성 여부, 신체적 기능상태가 제시되었다[5,6]. 수술 전 뇌종양의 크기가 5 cm 이상, 조직학적분화도에 따른 악성도가 높고, 수술 후 잔여종양이 많을수록, 혈관이 많은 뇌조직으로 침투될수록, 뇌경막으로의 침범에 따른 다발성일 때, 진단 초기 환자의 신체적 기능상태가 낮을 때 환자의 예후는 좋지 않은 것으로알려져있다[7,8]. |
The Korean Brain Tumor Society. Brain Cancers Epidemiology Page[Internet]. [cited 2015 March 13]. Available from: http://www.braintumor.or.kr/public/infor/sub2_1.php.
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathologica. 2016; 131(6): 803-820. http://dx.doi.org/10.1007/s00401-016-1545-1
National Cancer Information Center. The Types of Brain Cancers Page [Internet]. [cited 2016 May 2]. Available from:http://www.cancer.go.kr/mbs/cancer/jsp/cancer/cancer.jsp?cancerSeq4301&menuSeq4302&viewTypeall&idcancer_020118000000.
Kim BS, Seol HJ, Nam DH, Park CK, Kim IH, Kim TM, Kim JH et al. Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea. Cancer Research and Treatment. 2017;49(1):193-203. http://dx.doi.org/10.4143/crt.2015.473
Sarica FB, Cekinmez M, Tufan K, Sen O, Onal HC, Mertsoylu H et al. Five-year follow-up results for patients diagnosed with anaplastic astrocytoma and effectiveness of concomitant therapy with temozolomide for recurrent anaplastic astrocytoma. Asian Journal of Neurosurgery. 2012; 7(4): 181-190. http://dx.doi.org/10.4103/1793-5482.106650
Kumar N, Kumar P, Angurana SL, Khosla D, Mukherjee KK, Aggarwal R et al. Evaluation of outcome and prognostic factors in patients of glioblastoma multiforme: A single institution experience. Journal of Neurosciences in Rural Practice. 2013;4(5):46-55. http://dx.doi.org/10.4103/0976-3147.116455
Marina O, Suh JH, Reddy CA, Barnett GH, Vogelbaum MA, Peereboom DM et al. Treatment outcomes for patients with glioblastoma multiforme and a low Karnofsky Performance Scale score on presentation to a tertiary care institution. Clinical article. Journal of Neurosurgery. 2011;115(2):220-229. http://dx.doi.org/10.3171/2011.3.JNS10495
Roy S, Lahiri D, Maji T, Biswas J. Recurrent Glioblastoma: Where we stand. South Asian Journal of Cancer. 2015;4(4):163-173. http://dx.doi.org/10.4103/2278-330X.175953
Millan J, Pinto X, Munoz A, Zuniga M, Rubies-Prat J, Pallardo LF et al. Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention. Vascular Health and Risk Management. 2009; 5:757-765. https://doi.org/10.2147/VHRM.S6269
Bielecka-Dabrowa A, Hannam S, Rysz J, Banach M. Malignancy-associated dyslipidemia. Open Cardiovascular Medicine Journal.2011;5:35-40. https://do i.org/10.2174/1874192401105010035
Conklin KA. Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integrative Cancer Therapies.2004;3(4):294-300. https://doi.org/10.1177/1534735404270335
Nelson RH. Hyperlipidemia as a Risk Factor for Cardiovascular Disease. Prim Care. 2013;40(1):195-211. https://doi.org/10.1016/j.pop.2012.11.003
Upadhyay RK. Emerging Risk Biomarkers in Cardiovascular Diseases and Disorders. Journal of Lipids. 2015;8:971453. https://doi.org/10.1155/2015/971453
Ghahremanfard F, Mirmohammadkhani M, Shahnazari B, Gholami G, Mehdizadeh J. The Valuable Role of Measuring Serum Lipid Profile in Cancer Progression. Oman Med J. 2015;3(5):353-357. https://doi.org/10.5001/omj.2015.71
Allott EH, Howard LE, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK et al. Serum lipid profile and risk of prostate cancer recurrence: results from the SEARCH database. Cancer Epidemiol Biomarkers Prev. 2014;23(11):2349-2356. https://doi.org/10.1158/1055-9965.EPI-14-0458
Gupta RK, Patel AK, Kumari R, Chugh S, Shrivastav C, Mehra S et al. Interactions between oxidative stress, lipid profile and antioxidants in breast cancer: a case control study. Asian Pacific Journal of Cancer Prevention. 2012;13(12): 6295-6298. https://doi.org/10.7314/APJCP.2012.13.12.6295
McGrowder D, Riley C, Morrison EY, Gordon L. The Role of High-Density Lipoproteins in Reducing the Risk of Vascular Diseases, Neurogenerative Disorders, and Cancer. Cholesterol. 2011:1-9. https://doi.org/10.1155/2011/496925
Mallick S, Benson R, Hakim A, Rath GK. Management of glioblastoma after recurrence: A changing paradigm. Journal of the Egyptian National Cancer Institute. 2016;28(4):199-210. http://dx.doi.org/10.1016/j.jnci.2016.07.001
Yao X, Tian Z. Dyslipidemia and colorectal cancer risk: a meta-analysis of prospective studies. Cancer Causes & Control. 2015;26(2):257-268. https://doi.org/10.1007/s10552-014-0507-y
Givens DJ, Karnell LH, Gupta AK, Clamon GH, Pagedar NA, Chang KE et al. Adverse events associated with concurrent chemoradiation therapy in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2009; 135(12): 1209-1217. https://doi.org/10.1001/archoto.2009.174
Li J, Wu MF, Lu HW, Zhang BZ, Wang LJ, Lin ZQ. Impact of Hyperglycemia on Outcomes among Patients Receiving Neoadjuvant Chemotherapy for Bulky Early Stage Cervical Cancer. PLoS One. 2016;11(11):1-15. http://dx.doi.org/10.1371/journal.pone.0166612
Huang C, Freter C. Lipid Metabolism, Apoptosis and Cancer Therapy. International Journal of Molecular Sciences. 2015;16(1):924-949. https://doi.org/10.3390/ijms16010924.
Wang Y, Wang ZQ, Wang FH, Lei XF, Yan SM, Wang DS et al. Predictive value of chemotherapy-related high-density lipoprotein cholesterol (HDL) elevation in patients with colorectal cancer receiving adjuvant chemotherapy: an exploratory analysis of 851 cases. Oncotarget.2016;7(35):57290-57300. https://doi.org/10.18632/oncotarget.10145
Dai D, Chen B, Wang B, Tang H, Li X, Zhao Z et al. Pretreatment TG/HDL-C Ratio Is Superior to Triacylglycerol Level as an Independent Prognostic Factor for the Survival of Triple Negative Breast Cancer Patients. Journal of Cancer.2016;7(12):1747-1754. https://doi.org/ 10.7150/jca.15776
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
오픈액세스 학술지에 출판된 논문
※ AI-Helper는 부적절한 답변을 할 수 있습니다.